Trends in diabetes

Lancet

Volumn 369, Issue 9569, 2007, Pages 1257-

  Theleritis, Christos G ^a   Psarros, Constantin ^a   Papadimitriou, George N ^a   Soldatos, Constantin R ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT;

BIPOLAR DISORDER; BODY MASS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG USE; HUMAN; LETTER; LIFESTYLE; METABOLIC DISORDER; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING; NOTE;

BIPOLAR DISORDER; DIABETES MELLITUS, TYPE 2; HUMANS; LIFE STYLE; PREVALENCE;

EID: 34047276137     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60589-3     Document Type: Letter

References (5)

1. Lipscombe L., and Hux J. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet 369 (2007) 750-756
2. Expert Group. Schizophrenia and Diabetes 2003 Expert Consensus Meeting, Dublin, Oct 3-4, 2003: consensus summary. Br J Psychiatry 184 suppl 47 (2004) s112-s114
3. Newcomer J. Medical risks in patients with bipolar disorder and schizophrenia. J Clin Psychiatry 67 suppl 9 (2006) 25-30
4. Nasrallah H., Meyer J., Goff D., et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schiz Res 86 (2006) 15-22
5. Pawlak D., Kushner J., and Ludwig D. Effects of dietary glycaemic index on adiposity, glucose homoeostasis, and plasma lipids in animals. Lancet 364 (2004) 778-785